Juno Therapeutics Inc (NASDAQ:JUNO) Director Richard Klausner sold 12,724 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $48.21, for a total transaction of $613,424.04. Following the completion of the sale, the director now owns 741,499 shares in the company, valued at approximately $35,747,666.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Richard Klausner also recently made the following trade(s):
- On Thursday, December 21st, Richard Klausner sold 36,000 shares of Juno Therapeutics stock. The stock was sold at an average price of $44.76, for a total transaction of $1,611,360.00.
Shares of Juno Therapeutics Inc (JUNO) opened at $49.21 on Wednesday. Juno Therapeutics Inc has a fifty-two week low of $18.90 and a fifty-two week high of $63.45. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. The company has a market cap of $5,620.00, a P/E ratio of -14.52 and a beta of 2.32.
Large investors have recently bought and sold shares of the company. Advisor Group Inc. grew its holdings in shares of Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Juno Therapeutics during the second quarter valued at approximately $105,000. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the last quarter. Finally, QS Investors LLC purchased a new stake in shares of Juno Therapeutics during the second quarter valued at approximately $135,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Needham & Company LLC assumed coverage on shares of Juno Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $65.00 price objective on the stock. Maxim Group set a $56.00 price objective on shares of Juno Therapeutics and gave the stock a “buy” rating in a report on Wednesday, December 13th. Raymond James Financial restated a “buy” rating on shares of Juno Therapeutics in a report on Monday, December 11th. Wells Fargo & Co cut shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. Juno Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $46.70.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/10/juno-therapeutics-inc-juno-director-richard-klausner-sells-12724-shares.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.